FDA Inspection
Kite Pharma, Inc.Kite Pharma, Inc. – FDA Inspection, Aug 27, 2025
Record Details
This FDA Inspection record concerns Kite Pharma, Inc., with an inspection on August 27, 2025, issued by the Los Angeles District Office, covering biologics.
View Company Profile
ID · 6c854143-66e4-4bfa-b0da-a4e4e9b83d60
Inspection Facts
Voluntary Action Indicated (VAI)
Objectionable conditions were found, but FDA is not prepared to take or recommend regulatory action.
- Inspection number
- 1279894
- FDA center
- Biologics
- Project area
- Human Cellular, Tissue, and Gene Therapies
FDA Citations
4- 21 CFR 211.100(a)Absence of Written Procedures
- 21 CFR 211.192Written record of investigation incomplete
- 21 CFR 211.56(b)Written sanitation procedures lacking
- 21 CFR 211.68(b)input/output verification
Full citation text and observation details available on the Dashboard.
Other FDA inspections of Kite Pharma, Inc.
3| Date | Classification | Office | Project area |
|---|---|---|---|
| October 22, 2021 | VAI | Center for Biologics Evaluation and Research | Human Cellular, Tissue, and Gene Therapies |
| August 20, 2019 | VAI | Center for Biologics Evaluation and Research | Human Cellular, Tissue, and Gene Therapies |
| June 16, 2017 | Not classified | Los Angeles District Office |
Other documents for Kite Pharma, Inc.
- FDA Inspection 1155166 - 2021-10-22
- FDA Inspection 1100058 - 2019-08-20
- FDA Inspection 1015808 - 2017-06-16
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.